Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc. reports news as a global oncology company developing and commercializing targeted cancer therapies. Its updates center on IBTROZI® (taletrectinib), an oral, CNS-active, selective next-generation ROS1 inhibitor approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, as well as regulatory submissions, clinical data from TRUST studies, guideline inclusion, and commercialization activity.
Company news also covers safusidenib, a brain-penetrant IDH1 inhibitor for IDH1-mutant glioma, and Nuvation Bio's drug-drug conjugate program. Recurring corporate items include licensing and collaboration arrangements, product-rights updates, investor conference participation, operating results, financial results, capital-structure disclosures, and governance matters.
Nuvation Bio (NYSE: NUVB) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Efficacy and safety data from the Phase 2 TRUST-I study of taletrectinib published in the Journal of Clinical Oncology and presented at ASCO 2024
- Pooled data from TRUST-I and TRUST-II studies to be presented at ESMO 2024, supporting planned NDA filing
- Taletrectinib granted Orphan Drug Designation by FDA for ROS1-positive NSCLC
- Strong balance sheet with $577.2 million in cash and equivalents as of June 30, 2024
- Q2 2024 net loss of $462.5 million, or $(1.89) per share, compared to $20.6 million in Q2 2023
- R&D expenses increased to $29.2 million, up from $18.6 million in Q2 2023
Nuvation Bio (NYSE: NUVB) announced updates for its taletrectinib program, a ROS1 inhibitor for non-small cell lung cancer (NSCLC). Key highlights include:
- Presentation of pooled data from pivotal Phase 2 TRUST-I and TRUST-II studies at ESMO Congress 2024, supporting the New Drug Application (NDA) in the US
- Presentation of global Phase 2 TRUST-II study data at WCLC 2024
- FDA granted Orphan Drug Designation for taletrectinib in ROS1-positive NSCLC and other NSCLC indications
The company aims to commercialize taletrectinib in 2025. The Orphan Drug Designation provides development incentives, including tax credits and potential market exclusivity. Taletrectinib is being evaluated in two pivotal Phase 2 studies for ROS1-positive NSCLC patients.
Innovent Biologics announced updated data from its pivotal Phase 2 TRUST-I study of taletrectinib, a next-generation ROS1 inhibitor, published in the Journal of Clinical Oncology and presented at the 2024 ASCO Annual Meeting. The study involved 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) in China. Results showed a 91% confirmed objective response rate (cORR) in ROS1 TKI-naïve patients and a 52% cORR in those previously treated with crizotinib. Taletrectinib demonstrated favorable outcomes in patients with brain metastases and resistance mutations. The median duration of response and progression-free survival were not reached in TKI-naïve patients after a median follow-up of 23.5 months, while TKI-pretreated patients had a median duration of response of 10.6 months and median progression-free survival of 7.6 months. The safety profile was consistent with previous reports. Two new drug applications have been accepted for priority review by China's NMPA.
Innovent Biologics announced publication of Phase 2 TRUST-I study results in the Journal of Clinical Oncology and at the 2024 ASCO Annual Meeting. The study evaluated taletrectinib in 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). Tumor shrinkage was observed in 91% of ROS1 TKI-naïve and 52% of TKI-pretreated patients. Taletrectinib showed efficacy in treating brain metastases and resistance mutations. Median follow-up was 23.5 months for TKI-naïve and 9.7 months for TKI-pretreated patients. Median duration of response was not reached for TKI-naïve and was 10.6 months for TKI-pretreated. Two new drug applications have been accepted by China's NMPA with priority review. The safety profile showed low incidence of neurologic adverse events.
Nuvation Bio has published data from its Phase 2 TRUST-I study of taletrectinib, a ROS1 inhibitor, in the Journal of Clinical Oncology and presented at the 2024 ASCO Annual Meeting.
This study involved 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) in China. Results showed that tumors shrank in 91% of ROS1 TKI-naïve and 52% of ROS1 TKI-pretreated patients.
Long-term follow-up indicated 71% of TKI-naïve patients remained progression-free at two years. The study highlighted taletrectinib's effectiveness in patients with brain metastases and resistance mutations.
Safety profile was consistent with previous reports, showing low incidence of neurologic treatment-emergent adverse events.
Nuvation Bio, a late clinical-stage biopharmaceutical company focused on oncology, announced that its CEO, David Hung, M.D., will present at the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 1:30 p.m. ET. A live webcast of the presentation will be available on the Nuvation Bio website, with an archived recording accessible for 90 days.
Nuvation Bio (NYSE: NUVB) reported its Q1 2024 financial results, highlighted by the acquisition of AnHeart Therapeutics, transforming it into a late-stage oncology company. Updated data from the Phase 2 TRUST-I study of taletrectinib, a ROS1 inhibitor, will be presented at the 2024 ASCO Annual Meeting. The company also initiated a Phase 1/2 study of NUV-1511, a drug-drug conjugate for advanced solid tumors.
As of March 31, 2024, Nuvation Bio had $597.0 million in cash and securities. Q1 research and development expenses were $12.8 million, down from $18.8 million in Q1 2023, while general and administrative costs were $7.3 million, slightly down from $7.7 million. The net loss was $14.8 million, or $(0.07) per share, compared to $21.7 million, or $(0.10) per share, in Q1 2023.
Summary not available.
Summary not available.
Summary not available.